ReviewFuture microbiology2025
Resistance in gram-negative bacilli: the emergence of RND efflux pumps.
Review in Future microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bovine Mastitis Therapy at a Crossroads: Pharmacokinetic Barriers, Biofilms, Antimicrobial Resistance, and Emerging Solutions.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Whole-Genome Insights Into Tigecycline-ResistantTransboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rise of antimicrobial resistance has been a significant problem in recent decades, decreasing the effectiveness of antibiotics and making the treatment of infections increasingly difficult. This phenomenon can be acquired through various mechanisms, with antibiotic efflux mediated by proteins known as efflux pumps being one of the most important. Currently, these protein systems are classified into six major families. The resistance-nodulation-cell division (RND) superfamily significantly contributes to multidrug resistance, particularly against tetracyclines, aminoglycosides, β-lactams, macrolides, and fluoroquinolones. This is largely due to its broad substrate specificity and widespread distribution among Gram-negative bacteria, including members of the Enterobacterales order and non-fermenting bacilli, with pumps connecting the inner and outer membranes throughout the periplasm and forming complexes that efficiently expel antibiotics from the cell. Given the importance of these efflux proteins in bacterial resistance and physiology, several authors have sought to characterize and report new isolates and emerging pumps worldwide, as awareness of low antimicrobial susceptibility and its contributors can aid decision-making for infection control. Therefore, this study aimed to gather and analyze available data in the literature regarding the functioning and emergence of efflux pumps belonging to the RND family and highlight those with greater clinical importance, along with previously identified inhibitors to combat this resistance mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.